New ethnicities and British cultural studies Sample Clauses

New ethnicities and British cultural studies. The concept of new ethnicities has emerged out of a relatively new configuration of disciplines known as cultural studies. It originated in Birmingham in the 1960s when the Centre for Contemporary Cultural Studies (CCCS) was founded. Jamaican-born Xxxxxx Xxxx was an influential former director of the centre, and texts referring to the black experience of a ‘hybrid’ status within British society emerged from the Centre, while Xxxx himself has been referred to as a diasporic intellectual (Xxxx, 1996). Xxxx (1980) admitted that it is difficult to locate the exact beginnings of cultural studies and to give an exact definition but he states that: Cultural Studies was an ‘engaged’ set of disciplines, addressing awkward but relevant issues about contemporary society and culture, often without benefit of that scholarly detachment or distance which the passage of time alone sometimes confers on other fields of study (Hall, 1980 p. 4). In other words, cultural studies aimed to understand the changes and developments taking place in British society at the moment of such changes. There was a tension between political and intellectual concerns in cultural studies which according to Xxxx (1980, p. 80) ‘prevented its easy absorption and naturalization into the social division of knowledge’.
AutoNDA by SimpleDocs

Related to New ethnicities and British cultural studies

  • CULTURAL DIVERSITY The Cultural Diversity Requirement generally does not add units to a student's program. Rather, it is intended to be fulfilled by choosing courses from the approved list that also satisfy requirements in other areas of the student’s program; the exception is that Cultural Diversity courses may not satisfy Culture and Language Requirements for B.S. students. For example, Anthropology 2 can fulfill (3) units of the Behavioral Science requirement and (3) units of the Cultural Diversity requirement. This double counting of a class may only be done with the Cultural Diversity requirement. Courses in Cultural Diversity may be taken at the lower-division or upper-division level. U . S . H I S T O R Y I N S T I T U T I O N A L R E Q U I R E M E N T HIST 17A, 17B, 17C, 18A, 18B ICS 18A, 18B

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.